JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

Summary

This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.

Timeline

Start

2020-07-08

Primary completion

2023-06-13

Completion

2023-06-13

Outcome

Met primary endpoint

release “JSP191, when added to low-dose radiation and fludarabine, was well tolerated in all six patients” jaspertherapeutics.com ↗

Publications

• Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS. Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS. Blood. 2026 May 28;147(22):2610-2620. doi: 10.1182/blood.2025031858.

Drugs

Indications